For the Quarter Ending September 2023


North America

In the third quarter of 2023, the pricing dynamics of Clopidogrel Bisulfate API in North America closely mirrored trends observed in the Asia-Pacific (APAC) region. Throughout Q3, prices displayed a pessimistic trend primarily attributed to a decline in demand from the downstream sector. Both local and international suppliers noted a lack of new inquiries, with Indian suppliers possessing ample capacity to meet regional and local demands. Most new orders were volume-based, and the pre-festive holiday stocking in the downstream market led to a less optimistic market outlook. Moreover, a surplus of Clopidogrel Bisulfate persisted in the local spot market, allowing merchants to fulfill incoming requirements. Weaker manufacturing activity in the pharmaceutical sectors resulted from reduced consumer demand for specific drugs or their end products, driven by unfavorable weather conditions in the middle of Q3. Additionally, significant increases in shipping costs deterred many merchants from placing additional orders from exporting countries, contributing to the downward price trend throughout Q3.

Asia Pacific

Throughout the third quarter of 2023, the pricing trajectory of Clopidogrel Bisulfate API in the APAC region, particularly in India, remained weak. India's pharmaceutical and healthcare sectors witnessed a continuous decline, leading to decreased prices for various pharmaceutical APIs, including domestic IP and international USP grade Clopidogrel Bisulfate. On the other hand, prices of essential feedstock solvents like acetone, sulfuric acid, sodium hydroxide, and methanol, used in Clopidogrel production, increased, ensuring a sufficient supply in downstream industries. This resulted in a narrowed price difference between the feedstock and Clopidogrel Bisulfate in August 2023. Major industrial players are expected to reduce production in India due to persistently low demand in both domestic and international markets. Furthermore, India's Consumer Price Index (CPI) in September 2023 stood at 186.20 points, marking a 5.90% increase compared to September 2022, impacting the economic landscape. The negative demand outlook for Clopidogrel Bisulfate stems from shifting consumer preferences and intensified competition in the pharmaceutical sector. Suppliers, grappling with substantial stockpiles of Clopidogrel Bisulfate, had to adjust their pricing strategies to expedite product turnover.

Get Real Time Prices of Clopidogrel: https://www.chemanalyst.com/Pricing-data/clopidogrel-1529

Europe

Throughout the third quarter of 2023, Clopidogrel Bisulfate prices in the German market mirrored the trajectory observed in the APAC region. The consistent decrease in prices led to higher inventories among merchants and a weakened demand side. Contributing to this trend, the production of Clopidogrel Bisulfate API in exporting nations increased, resulting in a global surge in supply and subsequent downward pressure on prices. In August 2023, suppliers focused on replenishing their warehouse inventories, offering goods at consistently lower costs. The German manufacturing sector continued to contract, albeit at a slower rate than in July, indicated by the PMI reading. Supply chain disruptions, rising input costs, and weak demand were primary factors contributing to this contraction. The global economic downturn negatively impacted the demand for logistics services, and businesses, in uncertain times, were less willing to expand or invest in new projects. Market experts observed a rapid decline in prices since the beginning of 2023 due to high inventories and economic uncertainty, with the cautious approach of the downstream pharmaceutical industry potentially having short-term consequences.